Hydra Biosciences

Hydra Biosciences developed small molecule drugs targeting novel ion channels implicated in pain, inflammation, cardiovascular disease, anxiety disorders, renal fibrosis and more. Their most advanced programs reached up to Phase II clinical trials before the company underwent an asset sale. The company’s proprietary screening platforms enabled identification of selective modulators of TRP family ion channels—differentiating them from companies focused on classical sodium/calcium/potassium voltage-gated channels. As of the latest available information, Hydra Biosciences has ceased independent operations following an asset sale but retains a legacy portfolio of patents and scientific contributions in the field.